Results of Pivotal Phase 2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Year: 2018
Type: conference-abstract
Source: Blood
Authors: Naveen Pemmaraju, Andrew A. Lane, Kendra L. Sweet, Anthony S. Stein, Sumithira Vasu, William Blum, David A. Rizzieri, Eunice S. Wang, Madeleine Duvic, Sharon Spence, Shay Shemesh, Christopher Brooks, Ivan Bergstein, Janice Chen, Vanessa Dunn, Peter McDonald, John Mark Sloan, Jeffrey E. Lancet, Hagop M. Kantarjian, Marina Y. Konopleva
Institutions: The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, Moffitt Cancer Center, City Of Hope National Medical Center, Beckman Research Institute, The Ohio State University, Winship Cancer Institute, Duke Medical Center, Roswell Park Comprehensive Cancer Center, Stemline Therapeutics (United States), Boston University, Boston Medical Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2900550650